PROLANZA olanzapine 2.5mg tablet blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

olanzapine, Quantity: 2.5 mg

Commercializzato da:

Medis Pharma Pty Ltd

INN (Nome Internazionale):

Olanzapine

Forma farmaceutica:

Tablet, film coated

Composizione:

Excipient Ingredients: hyprolose; magnesium stearate; microcrystalline cellulose; crospovidone; lactose monohydrate; purified talc; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin

Via di somministrazione:

Oral

Confezione:

50, 40, 21, 14, 60, 28, 10, 30, 7, 20

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

For the treatment of schizophrenia and related psychoses. ,Alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. ,For preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.

Dettagli prodotto:

Visual Identification: White, round, biconvex film coated tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2011-08-11